VeriMomVeriMom
HIGH RISK

Стоит ли избегать naproxen при беременности? | VeriMom

Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.

ECHA regulatory hazard statements

  • H361

What to use instead

Pregnancy-safe ingredients that serve a similar function:

FAQ

Безопасен ли naproxen при беременности?
Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
Безопасен ли naproxen при грудном вскармливании?
Naproxen is excreted into breast milk in low amounts but has a long half‑life and case reports of infant effects; professional guidance (LactMed, NHS Specialist Pharmacy Service, MotherToBaby) recommends caution and short‑term use if needed and consideration of alternative NSAIDs with shorter half‑lives. Mechanism is passive transfer into milk consistent with systemic exposure; expected exposure from topical cosmetic use is low but measurable.
Безопасен ли naproxen для кожи малыша?
No infant‑specific dermal teratogenicity data were found; systemic hazard stems from naproxen’s known reproductive effects. For baby (0–3 yr) skin, exposure scoring is increased by +1 due to immature barrier and higher surface‑area‑to‑weight, so exposure is moderate if a naproxen‑containing topical product were used repeatedly. There is no evidence to raise hazard or mechanism above the adult systemic evidence without infant‑specific studies.
Как VeriMom оценивает naproxen?
VeriMom оценивает naproxen в 20/100 (высокий риск) на основе EU CosIng, классификаций ECHA и исследований PubMed.
Какие безопасные альтернативы naproxen при беременности?
См. наш список безопасных альтернатив naproxen с аналогичной функцией и классификацией без известных рисков.

Проверь любой состав за 2 секунды

Скачай VeriMom бесплатно — отсканируй любой продукт и мгновенно получи оценку безопасности при беременности.

Медицинская оговорка

Данная информация предоставлена исключительно в образовательных целях и не является медицинской рекомендацией. Оценки безопасности основаны на общедоступных данных и могут не отражать все риски. Всегда консультируйтесь с вашим врачом перед использованием любых средств во время беременности или грудного вскармливания.

Получите полный доступ в приложении VeriMom